Data from the POD1UM-303/InterAACT2 trial support the approval of retifanlimab/chemotherapy for patients with squamous cell carcinoma of the anal canal.
Approval Alert | Retifanlimab/Chemotherapy in Recurrent/Metastatic Anal Cancer
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will RLTs Be Integrated Into the Prostate Cancer Treatment Paradigm?
2
Casdatifan Monotherapy Achieves Clinical Activity in Late-Line Kidney Cancer
3
Dato-DXd Improves Survival in Recurrent Inoperable/Metastatic TNBC
4
Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors
5
